FDA Approval of VYONDYS 53™ (golodirsen) Injection to treat patients with Duchenne Muscular Dystrophy (DMD)

CAMBRIDGE, Mass., Dec. 12, 2019 (GLOBE NEWSWIRE)Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved VYONDYS 53™ (golodirsen). VYONDYS 53 is an antisense oligonucleotide from Sarepta’s phosphorodiamidate morpholino oligomer (PMO) platform, indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation amenable to exon 53 skipping.

Publisert av

Mia

Light a candle, let it burn. 🕯 Never give up the hope, let the darkness disapear. 🌅 Had a son with X-Linked Spinal Muscular Atrophy (SMAX2)